Collectively, our data suggest that the GPS2-PPARα partnership in hepatocytes coordinates the progression of NAFLD in mice and in humans and thus might be of therapeutic interest. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.